Just saw XRTX jumping over 40% overnight to $0.68 after they extended the deadline on their kidney disease program acquisition. Pretty wild move for a biotech stock. Apparently they're picking up this anti-fibrotic therapy called VB4-P5 from Vectus and now have until end of March 2026 to close the deal instead of the original 90-day window. Gives them more time to sort out the IP transfer stuff. The company's already got a decent pipeline going - they're working on treatments for gout, ADPKD, acute kidney injury, and diabetic nephropathy. So I guess the market liked the signal that they're serious about expanding in the kidney disease space. Interesting to watch how these biotech stocks move on acquisition news. You holding any of this or just watching the action?

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin